Latest Health Technology at CES 2021
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
Women’s Health
HIV Patient’s Detectable Viremia Linked to ART-Supplement Interaction
Prior to pregnancy, her viral load had been undetectable for more than 2 years.
Clinically Meaningful Pain Reduction Observed With Relugolix in Endometriosis Trial
Positive topline results were announced from the phase 3 SPIRIT 1 study investigating relugolix (Myovant Sciences), in combination with estradiol and norethindrone acetate, in women with pain associated with endometriosis.
Oral Contraceptive With Novel Estrogen Under FDA Review
The novel combined oral contraceptive pill includes estetrol 15mg (E4) and drospirenone 3mg (DRSP).
Position Statement Clarifies Benefits of Testosterone Therapy for Women
Testosterone only recommended for postmenopausal women with hypoactive sexual desire dysfunction
Type and Timing of Menopausal HRT Affect Risk for Breast Cancer
Some excess risk persists for >10 years after ceasing therapy; magnitude varies with duration of use
Pregnancy-Related Adverse Events Linked to Isotretinoin Persist Despite REMS Implementation
According to the findings of a recent retrospective analysis, pregnancy and pregnancy-related adverse events related to isotretinoin administration have dropped since the initiation of the iPLEDGE program by the Food and Drug Administration (FDA) in 2006, however reports of fetal exposure persist. The iPLEDGE program is a Risk Evaluation and Mitigation Strategy (REMS) that aims…
Draft Recommendation Promotes Screening Women for Anxiety
Teen, adult women, including pregnant women, should be assessed for anxiety as part of routine care
Novel Combined Oral Contraceptive Effective in Phase 3 Trial
Previous Phase 2 studies confirmed esterol has minimal impact on liver cells and metabolic pathways, as well as on coagulation parameters.
Osphena Approved for Moderate to Severe Vaginal Dryness Due to Menopause
The expanded approval was based on safety and efficacy data from a confirmatory Phase 3 randomized, double-blind, placebo-controlled multicenter study evaluating Osphena in patients with moderate to severe vaginal dryness.
